title: Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon).
abstract: We investigated whether a recombinant follicle stimulating hormone (FSH) (Puregon) can be administered less frequently and at lower doses during ovulation induction than is current practice. Patients (20-35 years, body mass index <30 kg/m(2)) with infertility and chronic anovulation secondary to polycystic ovarian syndrome and resistant to previous clomiphene treatment received (Puregon); 100 IU, n = 17 patients, or 50 IU, n = 10 patients) on alternate days. After 2 weeks and in the absence of follicular recruitment, doses were increased stepwise at weekly intervals (50 IU/alternate days). Twenty-two cycles out of 27 were ovulatory. There were six pregnancies, five from Puregon (100 IU) and one from Puregon (50 IU); four pregnancies proceeded to term. The duration of stimulation (mean, range) with Puregon (100 IU) was 16.4, 7-29 and Puregon (50 IU) 19.1, 8-38 days. The gonadotrophin doses administered (mean; range) were 689, 200-1800 IU (Puregon 50 IU) and 939, 400-2300 IU (Puregon 100 IU). We conclude that low dose alternate day Puregon treatment is suitable for this difficult patient group.
authors.affiliation: Department of Medicine, Hope Hospital, Salford, UK.
authors.forename: H M
authors.initials: HM
authors.lastname: Buckler
authors.forename: W R
authors.initials: WR
authors.lastname: Robertson
authors.forename: A
authors.initials: A
authors.lastname: Anderson
authors.forename: M
authors.initials: M
authors.lastname: Vickers
authors.forename: A
authors.initials: A
authors.lastname: Lambert
mesh_terms: D000328:Adult; D000858:Anovulation / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000627:therapeutic use; D043373:Follicle Stimulating Hormone, Human; D006728:Hormones / Q000097:blood; D006801:Humans; D010060:Ovulation; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D006728:Hormones; D011994:Recombinant Proteins; D002996:Clomiphene; D005640:Follicle Stimulating Hormone